COMPANY OVERVIEW
Crown Bioscience, a JSR Life Sciences company with operations in San Diego and Beijing, is a global leader in patient-derived tumor models for oncology drug development. Their HuTumorX platform combines the world's largest PDX collection with organoid technology for translational cancer research serving pharmaceutical and biotech clients worldwide.
HuTumorX PLATFORM
- 3,000+ PDX Models: Largest commercial patient-derived xenograft collection
- Patient-Derived Organoids: 3D tumor cultures from patient tissue maintaining heterogeneity
- Genomic Annotation: Full molecular characterization (WES, RNAseq, CNV, methylation)
- Treatment History: Clinical response data linked to model drug sensitivity
- Immuno-Oncology: Humanized mouse models (HuGEMM, HuCell) for checkpoint inhibitor testing
KEY APPLICATIONS
- Preclinical efficacy studies for oncology compounds across 30+ tumor types
- Biomarker discovery and validation for patient stratification
- Drug resistance mechanism studies (acquired and intrinsic)
- Combination therapy optimization
- Co-clinical trials matching PDX to patient responses
GLOBAL OPERATIONS
Crown Bioscience operates GLP-compliant facilities in the US, China, and Europe, providing seamless global study execution. Their Asian tumor models include unique genetic subtypes (e.g., EGFR-mutant NSCLC) prevalent in Asian populations but underrepresented in Western biobanks.